Clinical trials: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement…
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, Hyperlipidaemia
- Trial name
- NCT07025980
- Testing
- The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS
- Where
- Croatia
- Volunteers
- 114 people
- Sponsor
- Eva Cubric
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Healthy, Simple Steatosis (SS)
New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
The goal of this observational study is to learn if some components of blood or exhaled breath can diagnose people having more fat in their livers than is normal, because of their poorer metabolic health (for example, because of…
- Conditions
- Healthy, Simple Steatosis (SS), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Trial name
- NCT06647095
- Testing
- D-Limonene Gelcaps, Fish Oil Concentrate, 1000 Mg Oral Capsule
- Where
- 2 sites in Czechia
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- General University Hospital, Prague
Metabolic Dysfunction-Associated Steatotic Liver Disease, Acute Coronary Syndromes (ACS)
MPV as a Predictor for ACS in Patients With MASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume…
- Trial name
- MPV/ACS MASLD (NCT07487571)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults
The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction…
- Trial name
- NCT06121999
- Testing
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University
Metabolic Dysfunction-associated Steatotic Liver Disease
Reducing Barriers to Lifestyle Modification for Newly Diagnosed MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease.
- Trial name
- NCT06483711
- Testing
- Lifestyle Kit
- Volunteers
- 50 people
- Sponsor
- Stanford University
Liver Disease
Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated…
- Trial name
- NCT07682363
- Testing
- No treatment is given
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Children
Screening and Intervention of MASLD in Children
Non-alcoholic fatty liver disease (NAFLD) in children and adolescents has recently been renamed metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT06905795
- Testing
- Fibroscan test, Nutrition guidance, Increase physical activity
- Where
- China
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity
Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Although metabolically healthy obesity (MHO) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and hyperuricemia remains unclear.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolically Healthy Obesity, Hyperuricemia
- Trial name
- NCT07001865
- Where
- China
- Volunteers
- 17,040 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLD
This randomized, double-blind, placebo-controlled study evaluated whether Gdue®, a nutraceutical containing extracts of the brown algae Ascophyllum nodosum and Fucus vesiculosus together with chromium picolinate, could improve…
- Trial name
- GDUE (NCT07763626)
- Testing
- Brown Algae and Chromium Picolinate Supplement
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- University of Genova
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- NCT06493253
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- United States
- Volunteers
- 1,519 people
- Sponsor
- PharmaNest, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.
- Trial name
- NCT06318169
- Testing
- Pegozafermin
- Where
- 370 sites in United States, Argentina and 25 more
- Volunteers
- 1,350 people
- Sponsor
- Hoffmann-La Roche
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)
A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database
The primary objective of this study is to estimate the proportion of people with low/intermediate/high risk of advanced fibrosis in at risk Chinese population based on the European Association for the Study of the Liver (EASL)…
- Trial name
- IMPACT MASH (NCT06741111)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 1,233,970 people
- Sponsor
- Novo Nordisk A/S
Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25)
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
The purpose of this study is to learn whether the Paso weight loss program is feasible for Mexican and Central American patients with fatty liver disease.
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25), Metabolic Syndrome
- Trial name
- NCT06854185
- Testing
- Paso Program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Food Insecurity
Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity
This proposal addresses a critical gap in our understanding of the impact of household food insecurity (FI) on pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) severity.
- Trial name
- NCT07090083
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of California, San Francisco
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes
Antidiabetic Drugs for Steatotic Liver Disease
To investigate the synergic therapeutic effect of thiazolidinediones and SGLT2 inhibitor on metabolic dysfunction-associated steatotic liver disease, the effect of empagliflozin 10mg, pioglitazone 15mg monotherapy and combination…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases
- Trial name
- NCT03646292
- Testing
- Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Yonsei University
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction…
- Trial name
- SCOUT Echo-AI (NCT07216859)
- Testing
- AI-Enabled Identification (EchoNet-Liver)
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Kaiser Permanente